BioNTech's Covid Vaccine Could Treat Multiple Sclerosis

 The anti-covid vaccine produced by BioNTech and Pfizer could treat multiple sclerosis. The German pharmaceutical company has released the first data on the preclinical application of the principle of the COVID-19 vaccine.

In a study published Friday in the journal "ScienceBioNTech" shows it has successfully developed an mRNA vaccine tested on "complex models of multiple sclerosis in mice" where it has been shown to suppress the disease.

The new focus "addresses key areas of autoimmune disease treatment, such as systemic immunosuppressive therapy," BioNTech said of the study, which is being conducted by various research departments at the university's medical center. Johannes Gutenberg in Mainz, central Germany.

Anti-covid vaccine produced by BioNTech-Pfizer could treat autoimmune diseases

Autoimmune diseases such as multiple sclerosis (MS) are conditions in which the immune system stops working properly and attacks healthy tissues or cells in the body; Inflammation in MS destroys the protective myelin sheath that covers nerve fibers.

This destructive action disrupts the ability to transmit signals to nerve cells and tissues and causes a wide variety of neurological, sensory and motor symptoms that differ from individual to individual, according to BioNTech.

In all models studied in mice with Experimental Autoimmune Encephalomyelitis (EAE), the vaccine “could prevent symptomatic disease, and in mice with early disease, disease progression was reduced and motor functions have been restored, ”said the German company. .

The vaccine is based on messenger ribonucleic acid (mRNA) technology, which can inject instructions or molecules into the body that can cause cells to make certain proteins.

In the COVID-19 vaccine, BioNTech and Pfizer used mRNA to produce the S (Spike) protein of the SARS-CoV-2 coronavirus, the "key" the new virus uses to enter the cell.

Multiple sclerosis is a progressive autoimmune disease that affects the central nervous system and is usually diagnosed in young adults between the ages of 20 and 40, and three out of four patients are women.